Dateline City:
SAN DIEGO
SAN DIEGO--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today announced
results from a pre-specified exploratory analysis of the investigational
IMPROVE-IT study of more than 18,000 patients presenting with acute
coronary syndromes.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more